

29<sup>th</sup> July, 2022

The Dy. General Manager (Listing Dept.)  
BSE Limited,  
Corporate Relationship Dept.,  
1<sup>st</sup> Floor, New Trading Ring,  
P. J. Towers, Dalal Street, Fort,  
Mumbai - 400 001  
**(BSE Scrip Code: 500420)**

The Manager – Listing Dept.,  
National Stock Exchange of India Ltd.,  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G. Block,  
Bandra - Kurla Complex, Bandra (E),  
Mumbai – 400 051  
**(NSE Scrip Code: TORNTPHARM)**

Dear Sir,

**Re: Proceedings of 49<sup>th</sup> Annual General Meeting of the Company held on 29<sup>th</sup> July, 2022**

In terms of Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), we hereby inform you that the following business was transacted at the 49<sup>th</sup> Annual General Meeting (AGM) of the Company held through Video Conferencing on 29<sup>th</sup> July, 2022:

1. Approval and adoption of Standalone and Consolidated Financial Statements as at 31<sup>st</sup> March, 2022, including the Audited Balance Sheet as at 31<sup>st</sup> March, 2022, the Statement of Profit and Loss for the year ended on that date and reports of the Board of Directors and Auditors thereon.
2. Confirmation of payment of interim dividend of ₹ 25.00 per equity share of fully paid up face value of ₹ 5.00 each and declaration of final dividend of ₹ 23.00 including the special dividend of ₹ 15.00 per equity share of fully paid up face value of ₹ 5.00 each for the financial year ended 31<sup>st</sup> March, 2022.
3. Appointment of a Director in place of Jinesh Shah (holding DIN 00406498), Director, who retires by rotation and being eligible, offers himself for re-appointment.
4. To re-appoint Statutory Auditors and fix their remuneration:
5. Ratification of remuneration of cost auditors of the company for the year 2022-23.
6. Issuance of Equity Shares including Convertible Bonds / Debentures.

The above business were transacted by Remote e-voting and e-voting at the meeting as required under Companies Act, 2013, Listing Regulations and Ministry of Corporate Affairs General circular no. 20 read with Circular nos. 14 & 17 of 2020 and 03 of 2022. Declaration of Results of Voting along with Scrutinizer’s Report and Results of the voting as required under Regulation 44(3) of Listing Regulations will be disclosed to the Stock Exchanges separately.

Kindly take note of the above.



**TORRENT PHARMACEUTICALS LIMITED**

CIN : L24230GJ1972PLC002126

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL  
VP (LEGAL) & COMPANY SECRETARY